期刊
CURRENT OPINION IN BIOTECHNOLOGY
卷 48, 期 -, 页码 242-250出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.copbio.2017.07.007
关键词
-
资金
- Japan Science and Technology Agency (JST) Core Research for Evolutional Science and Technology (CREST) of Molecular Technologies
- Japan Society for the Promotion of Science (JSPS) [26220204]
- European Union's Horizon research and innovation programme under the Marie Sklodowska-Curie grant [657292]
- [P15333]
- Marie Curie Actions (MSCA) [657292] Funding Source: Marie Curie Actions (MSCA)
- Grants-in-Aid for Scientific Research [15F15333] Funding Source: KAKEN
The ready availability of potent peptide binders for any desired target highlights their potential impact as therapeutic agents. Despite their versatility, however, peptides tend to display unfavourable pharmacological properties, such as low bioavailability, high renal clearance and proteolytic degradation rates, and low cell permeability. Fortunately, an increasing number of promising strategies to produce novel peptides and furnish pre-existing scaffolds with more drug-like properties are now becoming available. These strategies include incorporation of non-proteinogenic amino acids, tag appendage to existing peptides and grafting onto scaffolds already possessing desirable pharmacokinetic properties. As a consequence, a variety of promising bioactive macrocyclic peptides have recently been discovered highlighting the promise of this class of molecules as future medicines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据